Preclinical studies demonstrate the ability of BIND's targeted nanoparticle technology to enhance the trafficking of cytotoxic agents
to cancer cells and increase efficacy, which, if confirmed in human trials, has the potential to improve outcomes for patients," said Scott Minick, President and Chief Executive Officer of BIND Biosciences.
AN-152 is a cytotoxic conjugate that is designed to achieve differential delivery, or targeting, of the cytotoxic agent
to cancer vs.
These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, that SPI-1620 may improve delivery of chemotherapy to tumors, that SPI-1620 might allow physicians to maximize efficacy of reduced cytotoxic agent
doses with resultant decreased toxicity to the normal organs, that SPI-1620 could have a broad range of applications for use in conjunction with radiation and chemotherapy in the treatment of cancer, the safety and efficacy of SPI-1620 and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact.
Preclinical studies have shown XR5944 to be a highly active and potent cytotoxic agent
The Company's TAP technology couples highly potent cytotoxic agents
with tumor-targeting antibodies to create effective new treatments for cancer with minimal damage to normal tissue.
Current treatments available in Canada for late-stage ovarian cancer are known to have a poor response rate, and the side effect profiles of cytotoxic agents
can limit their usage.
CAELYX is a long-circulating STEALTH(R) pegylated liposomal formulation of doxorubicin hydrochloride, a widely used cytotoxic agent
If approved by the EC, CAELYX(R) will be the only cytotoxic agent
approved in Europe to treat a solid tumor using ALZA's patented STEALTH(R) liposomal technology.
These agents (DM1, DM4) are derivatives of the cytotoxic agent
CINTREDEKIN BESUDOTOX is a recombinant protein consisting of a single molecule composed of two parts: a tumor-targeting molecule (Interleukin-13 or IL13) and a cytotoxic agent
(Pseudomonas Exotoxin, or PE38).
Under the terms of the agreement, ImmunoGen will evaluate the applicability of the antibody to deliver ImmunoGen's DM1 cytotoxic agent
specifically to cancer cells.
The company's lead product, Clearazidee, is a topical cytotoxic agent
for the treatment of cutaneous T-cell lymphoma (CTCL).